Sustainability
A global pioneer in the development of new drugs
SK Biopharmaceuticals strategically promotes global ESG management
through actively responding to ESG evaluation and participating in related initiatives.
| Evaluation Agencies | Results | |
|---|---|---|
 |
Morgan Stanley Capital International (MSCI) |
|
 |
ISS ESG |
B-, Acquired ‘Prime’ badge (2024) |
 |
Sustainalytics |
Received Medium risk rating (2024) |
 |
Dow Jones Sustainability Indexes (DJSI) |
Included in DJSI Korea Index (2024) |
 |
Carbon Disclosure Project (CDP) |
B
(Climate Change, 2023) |
 |
FTSE4Good |
Selected as a constituent in the Index (2024) |
 |
Korea Institute of Corporate Governance and Sustainability (KCGS) |
|
| Initiative | Overview | |
|---|---|---|
 |
UN Global Compact (UNGC) |
A voluntary initiative based on CEO commitments to implement universal sustainability principles and to take steps to support UN goals. |
 |
Pharmaceutical Supply Chain Initiative (PSCI) |
An initiative of pharmaceutical and healthcare companies who share a vision of better social, health, safety and environmental outcomes in the communities |